Clinical Trial Detail

NCT ID NCT02915783
Title A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eisai Inc.
Indications

chromophobe renal cell carcinoma

papillary renal cell carcinoma

renal cell carcinoma

collecting duct carcinoma

Therapies

Everolimus + Lenvatinib

Age Groups: adult senior

No variant requirements are available.